EMC8 expression in head and neck squamous cell carcinoma: Implications for poor prognosis and deficient CD8+ T cell infiltration
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.156255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Xiaoyuan Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, …. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, CD8-Positive T-Lymphocytes, Head and Neck Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shaanxi Province.
Abstract (Originalsprache)
Emerging evidence highlights the role of Endoplasmic Reticulum Membrane Protein Complex (EMC) subunits in tumorigenesis, yet the function of EMC8 (Endoplasmic Reticulum Membrane Protein Complex Subunit 8) in Head and Neck Squamous Cell Carcinoma (HNSCC) remains elusive. In this study, we found EMC8 is significantly upregulated in HNSCC tissues compared to adjacent normal tissues, at both mRNA and protein levels. Kaplan-Meier survival analyses demonstrated that high EMC8 expression is associated with poorer overall survival, disease-specific survival, and progression-free interval in HNSCC patients. Further exploration into the tumor microenvironment showed that EMC8 expression negatively correlates with the infiltration of multiple immune cells, particularly CD8 + T cells, which was validated in clinical samples where high EMC8 expression corresponded to reduced CD8 + T cell infiltration. Additionally, single-cell RNA sequencing data indicated that EMC8 expression is positively associated with dedifferentiation, hypoxia, and stemness properties of HNSCC cells. Collectively, EMC8 upregulation in HNSCC correlates with poor prognosis, reduced CD8 + T cell infiltration, and aggressive phenotypes, positioning it as a potential prognostic marker with mechanistic links to immune evasion and malignancy warranting deeper exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.
- School of Information Engineering, Chang'an University, Xi'an 710061, China.
- Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China. Electronic address: shaxiaoying1976@xjtufh.edu.cn.
- Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China. Electronic address: suifang@xjtufh.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shaanxi Province
Zitieren
APA
Ma, X., Shao, Z., Deng, J., Chen, G., Ma, J., Chen, Z., Zhang, Y., Han, P., Liu, J., Gao, S., Shao, Y., & Sui, F. (2025). EMC8 expression in head and neck squamous cell carcinoma: Implications for poor prognosis and deficient CD8+ T cell infiltration. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156255
Vancouver
Ma X, Shao Z, Deng J, Chen G, Ma J, Chen Z, et al. EMC8 expression in head and neck squamous cell carcinoma: Implications for poor prognosis and deficient CD8+ T cell infiltration. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.156255
BibTeX
@article{Ma2025,
author = {Ma, Xiaoyuan and Shao, Zhihua and Deng, Junyu and Chen, Guangze and Ma, Junchi and Chen, Zeren and Zhang, Yu and Han, Peng and Liu, Junsong and Gao, Shan and Shao, Yuan and Sui, Fang},
title = {EMC8 expression in head and neck squamous cell carcinoma: Implications for poor prognosis and deficient CD8+ T cell infiltration},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.156255}
}
EUVIMED